Biocartis Group NV Total Assets
Biocartis Group NV total assets. Based on the latest financial reports, Biocartis Group NV (BCART) holds total assets worth €112.98 Million EUR (≈ $132.09 Million USD) as of June 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BCART market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Biocartis Group NV (2012–2022)
Total assets of Biocartis Group NV from 2012 to 2022. This chart illustrates how Biocartis Group NV's total assets have evolved over time, based on quarterly financial data. See latest Biocartis Group NV stock price today for real-time trading data and today's change.
Biocartis Group NV - Asset Composition Analysis
Biocartis Group NV Total Assets Breakdown (December 2022)
Biocartis Group NV total assets breakdown as of December 2022. Biocartis Group NV's total assets of €112.98 Million consist of 61.2% current assets and 38.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 21.8% |
| Accounts Receivable | €17.91 Million | 15.7% |
| Inventory | €18.91 Million | 16.5% |
| Property, Plant & Equipment | €31.53 Million | 27.6% |
| Intangible Assets | €4.77 Million | 4.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2012–2022)
This chart illustrates how Biocartis Group NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BCART working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biocartis Group NV's current assets represent 61.2% of total assets in 2022, a decrease from 67.7% in 2012.
- Cash Position: Cash and equivalents constituted 21.8% of total assets in 2022, down from 61.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 15.0% in 2012.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.6% of total assets.
Biocartis Group NV Competitors by Total Assets
Key competitors of Biocartis Group NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Biocartis Group NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.15 | 2.33 | 4.48 |
| Quick Ratio | 1.60 | 1.56 | 3.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €37.22 Million | €34.36 Million | €70.50 Million |
Biocartis Group NV - Advanced Valuation Insights
This section examines the relationship between Biocartis Group NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.47 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -19.8% |
| Total Assets | €114.28 Million |
| Market Capitalization | $27.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biocartis Group NV's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biocartis Group NV's assets decreased by 19.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biocartis Group NV (2012–2022)
The table below shows the annual total assets of Biocartis Group NV from 2012 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | €114.28 Million ≈ $133.60 Million |
-19.79% |
| 2021-12-31 | €142.48 Million ≈ $166.57 Million |
-32.32% |
| 2020-12-31 | €210.52 Million ≈ $246.12 Million |
-21.54% |
| 2019-12-31 | €268.32 Million ≈ $313.70 Million |
+92.50% |
| 2018-12-31 | €139.38 Million ≈ $162.96 Million |
-23.07% |
| 2017-12-31 | €181.19 Million ≈ $211.83 Million |
+28.23% |
| 2016-12-31 | €141.31 Million ≈ $165.20 Million |
-4.77% |
| 2015-12-31 | €148.38 Million ≈ $173.47 Million |
+179.90% |
| 2014-12-31 | €53.01 Million ≈ $61.98 Million |
-11.86% |
| 2013-12-31 | €60.15 Million ≈ $70.32 Million |
-9.13% |
| 2012-12-31 | €66.19 Million ≈ $77.38 Million |
-- |
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more